(Q54405942)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

editorial

0 references

title

Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Vu H Duong

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Eric Padron

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Rami S Komrokji

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

2 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Hematology

26 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

485-487

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24083503%20AND%20SRC:MED&resulttype=core&format=json

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure

26 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884

Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884

BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884

Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2013.827884